Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leqembi
Biogen's monoclonal antibody for Alzheimer's disease.
Regulatory
Report: Spending on Leqembi could hit $3.5B in 2025, CMS says
The Centers for Medicare & Medicaid Services is expecting outlays on Alzheimer's drug Leqembi that far outpace the drugmaker's estimates next year.
Paige Minemyer
Apr 11, 2024 3:50pm
Few health plans have dedicated Alzheimer’s strategy: survey
Dec 19, 2023 3:37pm
Industry Voices—The beginning of the end for Alzheimer's?
Oct 26, 2023 12:00pm
CMS is removing PET scan restrictions for Alzheimer's patients
Oct 13, 2023 3:35pm
Broader Leqembi coverage could burden Medicare, critics warn
Jul 17, 2023 12:02pm
Not covering Alzheimer’s drugs could be costly for Medicare
Jun 12, 2023 8:00am
